Citation Impact
Citing Papers
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
2011
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
2010
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Human induced pluripotent stem cells and their use in drug discovery for toxicity testing
2013
Current oral treatments for erectile dysfunction
2002
Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials
1995
Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
2009
Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects
2006
Nitric oxide synthases: regulation and function
2011 Standout
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Novel therapeutic targets for the treatment of heart failure
2011
Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6*
1998
In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
2009
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
2016
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction
2006
Pediatric Pulmonary Hypertension
2013
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Oral Anticoagulant Therapy
2012 Standout
New Antithrombotic Drugs
2012
Antithrombotic Therapy for VTE Disease
2016 Standout
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Rivaroxaban
2011
Drug-Induced Hepatotoxicity
2003 Standout
Pulmonary Hypertension in Chronic Lung Diseases
2013
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
2013
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
2005
Antithrombotic Therapy for VTE Disease
2012 Standout
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
2003
Endothelial Dysfunction, Arterial Stiffness, and Heart Failure
2012
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Riociguat for the Treatment of Pulmonary Arterial Hypertension
2013
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
2009
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
2013
Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic Window
2004
Study on the Sternberg Paradigm in Cirrhotic Patients Without Overt Hepatic Encephalopathy
1998
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications
2008
Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome
2011
Updated Clinical Classification of Pulmonary Hypertension
2013 Standout
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists
2003
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis
2010
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
New anticoagulants: how to deal with treatment failure and bleeding complications
2011
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Cardiac Safety in Clinical Trials of Phosphodiesterase 5 Inhibitors
2005
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
2009
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
2012
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
2009
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
2005
Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998
2002 Standout
Visual attention in cirrhotic patients: A study on covert visual attention orienting
1998
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban
2010
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Tumor Angiogenesis
2008 Standout
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
3d Transition Metals for C–H Activation
2018 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk
2013
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications
2013
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
2008
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
2007
7-Fluoroindazoles as Potent and Selective Inhibitors of Factor Xa
2007
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Mechanisms of Diabetic Complications
2013 Standout
Ca2+Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase
2003 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2017 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury
2009
Aminoquinoline-directed, cobalt-catalyzed carbonylation of sulfonamide sp2 C–H bonds
2017
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The Halogen Bond
2016 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Design, Structure−Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors
2008
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
2020
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators
2008
Works of Georg Wensing being referenced
Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects
2003
Abstract 10732: BAY 94-8862 Exerts a Potent Natriuretic Effect in Healthy Male Subjects Pre-treated With Fludrocortisone: Findings From a Proof-of-concept Study
2012
Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58‐2667) in Healthy Male Volunteers
2008
Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study
2001
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
2005
Urinary sodium balance in patients with cirrhosis: Relationship to quantitative parameters of liver function
1997
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
2009
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease
1990
Visual event-related P300 potentials in early portosystemic encephalopathy
1992
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein
2011
Single‐Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63‐2521: An Ascending‐Dose Study in Healthy Male Volunteers
2008
Vardenafil Increases Penile Rigidity and Tumescence in Men with Erectile Dysfunction after a Single Oral Dose
2001
Phase I study of BAY 57–9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors
2006
The safety of healthy volunteers in First-in-Man trials – an analysis of studies conducted at the Bayer in-house ward from 2000 to 2005
2010
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
2007
Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
2009
Selective 5-HT1A-R-agonist Repinotan Prevents Remifentanil-induced Ventilatory Depression and Prolongs Antinociception
2011
Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first‐in‐man and relative bioavailability studies
2015